Welcome

RAS oncogenes were considered undruggable for decades. Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021. Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.

The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges. At the same time, we plan to nurture dialogue between clinicians, preclinical as well as industrial researchers to envision how current research may guide future clinical practice.

We are inviting basic researchers, clinicians, and pharmaceutical scientists to join us in Salamanca, Spain, in September 2023, at our symposium Targeting RAS: new avenues and challenges.

Targeting RAS
Symposium

13th – 15th
September
2023

Welcome

Targeting RAS, new challenges and avenues. RAS oncogenes were considered undruggable for decades.

Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021.

Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges.

At the same time, we plan to nurture dialogue between clinicians, preclinical as well as clinical industrial researchers to envision how current research may guide future clinical practice.

Program

13th september
14th september
15th september
13th september
13 September 2023
08:00

Registration

13 September
Time:  08:00 - 09:00
Location: 
08:45

Opening presentation / Welcome speech (Eugenio Santos, Director, Centro de Investigación del Cáncer, Salamanca, Spain)

13 September
Time:  08:45 - 09:00
Location: 
09:00

SESSION 1: RAS DRIVEN MECHANISMS DURING TUMOUR INITIATION & PROGRESSION - Chairperson: Eugenio Santos

13 September
Time:  09:00 - 10:30
Location: 
09:00

Challenges and opportunities in treating KRAS mutant tumors

Targeting RAS
13 September
Time:  09:00 - 09:30
Location: 
Speaker:  Shiva Malek
09:30

RAS mutation tropism

Targeting RAS
13 September
Time:  09:30 - 10:00
Location: 
Speaker:  Christopher Counter
10:00

Disruption of Immune Homeostasis Circuits in Mutant KRas Tumors

Targeting RAS
13 September
Time:  10:00 - 10:30
Location: 
Speaker:  Dafna Bar-Sagi
10:30

Short talk selected from abstracts | Olesja Popow, Dana-Farber Cancer Institute, Boston, USA “Dissecting The Tissue-Specific Oncogenic Activity Of K-RasG12D”

13 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

13 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 2: RAS & TUMOUR MICROENVIRONMENT - Chairperson: Esther Castellano

13 September
Time:  11:15 - 12:45
Location: 
11:15

Developing rational approaches to targeting RAS in combination with immune regulators

Targeting RAS
13 September
Time:  11:15 - 11:45
Location: 
Speaker:  Julian Downward
11:45

KRAS dependencies in Pancreatic Cancer

Targeting RAS
13 September
Time:  11:45 - 12:15
Location: 
Speaker:  David Tuveson
12:15

Enhancing immunotherapy in Kras driven lung cancer

Targeting RAS
13 September
Time:  12:15 - 12:45
Location: 
12:45

Short talk selected from abstracts | Alejandro Rosell, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain “RAS-PI3K signaling: a master regulator of CAF phenotype to promote lung tumor progression”

13 September
Time:  12:45 - 13:00
Location: 
13:00

Lunch & poster session

13 September
Time:  13:00 - 14:30
Location: 
14:30

SESSION 3: RAS MEMBRANE DYNAMICS & STRUCTURAL INSIGHTS - Chairperson: David Santamaría

13 September
Time:  14:30 - 16:00
Location: 
14:30

How can same-gene mutations promote both cancer and developmental disorders?

Targeting RAS
13 September
Time:  14:30 - 15:00
Location: 
Speaker:  Ruth Nussinov
15:00

Biological relevance of KRAS complexes interaction at the cell membrane

Targeting RAS
13 September
Time:  15:00 - 15:30
Location: 
Speaker:  Chiara Ambrogio
15:30

Drug combinations with novel PDE6D inhibitors release differentiation block of oncogenic KRAS

Targeting RAS
13 September
Time:  15:30 - 16:00
Location: 
Speaker:  Daniel Abankwa
16:00

Short talk selected from abstracts | Milla Kurki, University of Eastern Finland, Finland “Exploring mutation-specific differences of KRAS: conformational dynamics and implications for effector-protein preferences”

13 September
Time:  16:00 - 16:15
Location: 
16:15

Coffee break

13 September
Time:  16:15 - 16:45
Location: 
16:45

SESSION 4: RAS ISOFORMS AND SUPERFAMILY - Chairperson: Piero Crespo

13 September
Time:  16:45 - 18:15
Location: 
16:45

Ras variant abundance and biology

Targeting RAS
13 September
Time:  16:45 - 17:15
Location: 
Speaker:  Ian Prior
17:15

Proteomic profiling of KRAS signaling; Context, CAFs and Combinations

Targeting RAS
13 September
Time:  17:15 - 17:45
Location: 
Speaker:  Udai Banerji
17:45

«Out of the box» functions of RHOA mutations in peripheral T cell lymphoma

Targeting RAS
13 September
Time:  17:45 - 18:15
Location: 
Speaker:  Xosé R. Bustelo
18:15

Short talk selected from abstracts I | Greg G Jones, Pfizer, San Diego, California, USA “Targeting the RAS Pathway through a First-in-Class DOCK5 Degrader”

13 September
Time:  18:15 - 18:30
Location: 
18:30

Short talk selected from abstracts II | Fernando Calvo Baltanas, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain “Single and dual SOS1/SOS2 inhibition: evaluation of therapeutic effects and toxicity”

13 September
Time:  18:30 - 19:15
Location: 
18:45

End of day 1

13 September
Time:  18:4523:16
14th september
14 September 2023
09:00

SESSION 5: NOVEL THERAPEUTIC APPROACHES (PRECLINICAL PERSPECTIVE) - Chairperson: Matthias Drosten

14 September
Time:  09:00 - 11:00
Location: 
09:00

New ideas to target RAS

Sala Mayor, Fonseca
Targeting RAS
14 September
Time:  09:00 - 09:30
Location:  Sala Mayor, Fonseca
Speaker:  René Bernards
09:30

Targeting KRAS signalling

Targeting RAS
14 September
Time:  09:30 - 10:00
Location: 
Speaker:  Mariano Barbacid
10:00

Drug repurposing strategies for the treatment of mutant KRAS cancers

Targeting RAS
14 September
Time:  10:00 - 10:30
Location: 
Speaker:  Silve Vicent
10:30

Understanding the role of endogenous and mutated KRAS in homeostasis and transformation of the colon

Targeting RAS
14 September
Time:  10:30 - 11:00
Location: 
Speaker:  Owen Sansom
11:00

Short talk selected from abstracts | Monica Musteanu, Universidad Complutense, Madrid, Spain “Avutometinib and FAK inhibitor concomitant treatment enhances antitumor efficacy of sotorasib in mice harboring KRASG12C;p53 mutant lung adenocarcinomas”

14 September
Time:  11:00 - 11:15
Location: 
11:15

Coffee break

14 September
Time:  11:15 - 11:45
Location: 
11:45

SESSION 6: NOVEL THERAPEUTIC APPROACHES (CLINICAL PERSPECTIVE) - Chairperson: Pilar Garrido

14 September
Time:  11:45 - 13:45
Location: 
11:45

Strategies for Drugging Undruggable Targets in Oncology With New Covalent Warheads

Targeting RAS
14 September
Time:  11:45 - 12:15
Location: 
Speaker:  Kevan Shokat
12:15

Current and future challenges in the clinical development of KRAS G12C inhibitors in non-small cell lung cancer

Targeting RAS
14 September
Time:  12:15 - 12:45
Location: 
Speaker:  Ernest Nadal
12:45

Luis Paz Ares (Hospital Universitario 12 de Octubre, Madrid, Spain)

Targeting RAS
14 September
Time:  12:45 - 13:15
Location: 
Speaker:  Luis Paz-Ares
13:15

Applied biobanking to validate clinical vulnerabilities in RAS lung cancer variants

Targeting RAS
14 September
Time:  13:15 - 13:45
Location: 
Speaker:  Colin Lindsay
13:45

Short talk selected from abstracts | Katrin J. Frank, Klinikum rechts der Isar, Technical University Munich, Germany “Combination of the novel SHP2 inhibitor RMC-4550 and the novel ERK inhibitor LY3214996 for the treatment of KRAS mutant pancreatic cancer”

14 September
Time:  13:45 - 14:00
Location: 
14:00

Lunch & poster session

14 September
Time:  14:00 - 15:15
Location: 
15:15

SESSION 7: NOVEL THERAPEUTIC APPROACHES (PHARMACEUTICAL PERSPECTIVE) - Chairperson: Julian Downward

14 September
Time:  15:15 - 17:15
Location: 
15:15

Using Tri-Complex RAS(ON) Inhibitors to Target RAS

Targeting RAS
14 September
Time:  15:15 - 15:45
Location: 
Speaker:  Mathew Holderfield
15:45

Progress on selective targeting of KRAS mutant alleles and emerging clinical implications

Targeting RAS
14 September
Time:  15:45 - 16:15
Location: 
Speaker:  James Christensen
16:15

Targeting RAS-Driven PI3Kα Activation in Human Tumors

Targeting RAS
14 September
Time:  16:15 - 16:45
Location: 
Speaker:  Pedro Beltran
16:45

Targeting KRAS via SOS1: Parallel Fragment Screening and HTS Approach

Targeting RAS
14 September
Time:  16:45 - 17:15
Location: 
Speaker:  Barbara Nicke
17:15

A clinical update on AMGEN's KRAS G12C-selective inhibitor Sotorasib and pre-clinical studies on a novel multi-KRAS inhibitor

Targeting RAS
14 September
Time:  17:15 - 17:45
Location: 
Speaker:  Rati Verma
17:45

Short talk selected from abstracts | Barbara Mair, Boehringer Ingelheim RCV, Vienna, Austria “Assessment of KRAS mutant allele binding by covalent and non-covalent inhibitors through a cellular Switch-I/II and Switch-II pocket target engagement assay”

14 September
Time:  17:45 - 00:00
Location: 
18:00

Coffee break

14 September
Time:  18:00 - 18:30
Location: 
18:30

SESSION 8: TREATMENTS & COMBINATIONS TO COME (ROUND TABLE) - Chairperson: René Bernards

14 September
Time:  18:30 - 19:15
Location: 
18:30

Participants from pharma, clinic and academia (TBD)

14 September
Time:  18:30 - 19:15
Location: 
19:30

End of day 2

14 September
Time:  19:30 - 23:16
Location: 
20:30

Meeting dinner: Palacio de Figueroa - Calle Zamora, 15, 37002 Salamanca

14 September
Time:  20:30 - 22:30
15th september
15 September 2023
09:00

SESSION 9: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (I) - Chairperson: Silve Vicent

15 September
Time:  09:00 - 10:30
Location: 
09:00

A perfect storm - Formation of Ras - Raf signalosome and its implications

Targeting RAS
15 September
Time:  09:00 - 09:30
Location: 
Speaker:  Yibing Shan
09:30

Three Rs: RNA Regulates RAS-ERK signals

Targeting RAS
15 September
Time:  09:30 - 10:00
Location: 
Speaker:  Piero Crespo
10:00

The SHOC2/MRAS/PP1 complex as a therapeutic target for RAS-driven cancers

Targeting RAS
15 September
Time:  10:00 - 10:30
Location: 
10:30

Short talk selected from abstracts | Mukund Sharma, University of Turku, Finland “Convergence of RAS and PP2A activity on the phosphoregulation of chromatin repressor complexes”

15 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

15 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 10: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (II) - Chairperson: Mariano Barbacid

15 September
Time:  11:15 - 12:45
Location: 
11:15

Back to the future: the role of RAF kinases in RAS signaling and transformation

Targeting RAS
15 September
Time:  11:15 - 11:45
Location: 
Speaker:  Walter Kolch
11:45

Targeting the KRAS-ERK-MYC signaling network for the treatment of KRAS-mutant pancreatic cancer

Targeting RAS
15 September
Time:  11:45 - 12:15
Location: 
Speaker:  Channing J. Der
12:15

Ras-effector networks in (patho)physiological contexts

Targeting RAS
15 September
Time:  12:15 - 12:45
Location: 
Speaker:  Christina Kiel
12:45

Short talk selected from abstracts | Patricia Santofimia Castaño, Centre de Recherche en Cancérologie de Marseille, INSERM, France “Targeting NUPR1-dependet Stress Granules Formation as an Efficient Strategy to Induce Synthetic Lethality In KrasG12D-Dependent Tumors”

15 September
Time:  12:45 - 13:00
Location: 
13:00

SESSION 11: CLOSING LECTURE

15 September
Time:  13:00 - 13:45
Location: 
13:00

The End of KRAS cancers?

Targeting RAS
15 September
Time:  13:00 - 13:30
Location: 
Speaker:  Frank McCormick
13:45

End of meeting

15 September
Time:  13:45 - 15:00

Speakers

Colin Lindsay

Christie NHS Foundation Trust, University of Manchester, Manchester, UK

Ernest Nadal

Ernest Nadal (Catalan Institute of Oncology (ICO); Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain)

Frank McCormick

National Cancer Institute RAS Initiative (Frederick National Laboratory for Cancer Research, Frederick, MD) & University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, USA.

Ian Prior

University of Liverpool, Liverpool, UK

Kevan Shokat

Howard Hughes Medical Institute, Maryland, USA & University of California San Francisco (UCSF), San Francisco, USA & University of California (UC Berkeley), Berkeley, USA.

Owen Sansom

Beatson Institute for Cancer Research, Glasgow. UK

Pilar Garrido

Hospital Universitario Ramón y Cajal & Universidad de Alcalá

Shiva Malek

Novartis Institutes for Biomedical Research, Boston, USA

Walter Kolch

Systems Biology Ireland, University College Dublin, Dublin, Ireland

Registration

Event Location

palacio congresos de salamanca

Palacio de Congresos Salamanca

Cuesta de Oviedo, S/N, 37008 Salamanca
Suitable for conferences, performances and shows.
 

Targeting RAS – New challenges and avenues  has been made possible thanks to:

logo-CIC
1280px-Logotipo_del_CSIC
marca-UniversidadSalamanca-color
Do you want to enjoy and benefit from the knowledge of world-renowned researchers?

Any questions?
Ask us

If you need additional information or would like to know any specific details, please contact us.